Cargando…

Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib

Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib are primarily used in the initial treatment of chronic phase (CP)-chronic myeloid leukemia (CML), as CMLs harbor the BCR-ABL fusion product. An increased number of lymphocytes and large granular lymphocytes (LGLs) have be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Tatsuro, Noguchi, Kazuhiro, Hayashi, Shizuka, Irie, Sadaharu, Hayase, Risa, Shioya, Haruna, Kaneko, Youhei, Horio, Kensuke, Taguchi, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778875/ https://www.ncbi.nlm.nih.gov/pubmed/29435021 http://dx.doi.org/10.3892/ol.2017.7720

Ejemplares similares

Induction of Effector and Memory Cellular Immunity in a Patient with Long-Term Complete Molecular Response to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Jo, Tatsuro, et al.
Publicado: (2020)

Elevation of Memory Cytotoxic T Lymphocytes, Including Human T Lymphotropic Virus Type 1 Tax-Specific and Hepatitis Virus Type C-Specific Cytotoxic T Lymphocytes, in a Patient with Adult T-Cell Leukemia/Lymphoma and Hepatocellular Carcinoma
por: Jo, Tatsuro, et al.
Publicado: (2020)

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
por: Jo, Tatsuro, et al.
Publicado: (2020)

Live attenuated VZV vaccination induces antitumor immunity in ATLL patients
por: Jo, Tatsuro, et al.
Publicado: (2022)

Clonal Upregulation of Effector Cytotoxic T Lymphocytes in a Patient with Multiple Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia with Long-Term Survival
por: Jo, Tatsuro, et al.
Publicado: (2021)

HTLV‐1 Tax‐specific memory cytotoxic T lymphocytes in long‐term survivors of aggressive‐type adult T‐cell leukemia/lymphoma
por: Jo, Tatsuro, et al.
Publicado: (2022)

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
por: Kumagai, Takashi, et al.
Publicado: (2017)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
por: Gadó, Klára, et al.
Publicado: (2012)

Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab
por: Jo, Tatsuro, et al.
Publicado: (2014)

Dasatinib suppresses particulate-induced pyroptosis and acute lung inflammation
por: Pan, Yixi, et al.
Publicado: (2023)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Maintaining Weight and Nutritional Status with Ninjin’yoeito in Elderly Patients with Chronic Wasting Diseases
por: Nakagawa, Yumi, et al.
Publicado: (2022)

Dasatinib attenuates airway inflammation of asthma exacerbation in mice induced by house dust mites and dsRNA
por: Nishimoto, Yuki, et al.
Publicado: (2022)

Dasatinib in chronic myeloid leukemia: a review
por: Aguilera, Dolly G, et al.
Publicado: (2009)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

The role of dasatinib in the management of chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015)

Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine
por: Jo, Tatsuro, et al.
Publicado: (2012)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019)

Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia
por: Suyama, Takahiro, et al.
Publicado: (2023)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
por: Lima, Lisa M, et al.
Publicado: (2010)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
por: Serpa, Mariana, et al.
Publicado: (2010)

Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib
por: Takekoshi, Daisuke, et al.
Publicado: (2020)

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Maat, Zakaria, et al.
Publicado: (2021)

Haemorrhagic Colitis Caused by Dasatinib
por: Patodi, Nishant, et al.
Publicado: (2012)

Dasatinib-induced Pulmonary Hypertension
por: Tamura, Yudai, et al.
Publicado: (2022)

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission
por: Kumagai, Takashi, et al.
Publicado: (2020)

Dipeptidyl‐peptidase 4 inhibitor increased and maintained platelet count in a patient with primary myelofibrosis
por: Kaneko, Shizuka, et al.
Publicado: (2021)

The barriers to smoking cessation in Swiss methadone and buprenorphine-maintained patients
por: Wapf, Victoria, et al.
Publicado: (2008)

A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
por: Nekoukar, Zahra, et al.
Publicado: (2021)

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study
por: Mizuta, Shuichi, et al.
Publicado: (2018)

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
por: Haslam, Sonya
Publicado: (2005)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4sqac176fs5rokm2sdnqgjskd1